Literature DB >> 8338926

Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital.

R Mathias1, I Salusky, W Harman, A Paredes, J Emans, G Segre, W Goodman.   

Abstract

Renal bone disease has been well defined in adult patients receiving chronic dialysis and in children on peritoneal dialysis/continuous ambulatory peritoneal dialysis. However, little is known about the histologic features in patients undergoing chronic hemodialysis in a children's hospital center. Twenty one patients, aged 17.5 +/- 1.5 yr, on hemodialysis for 35 +/- 6 months underwent iliac crest bone biopsies and deferoxamine infusion tests. Nineteen of 21 patients were receiving oral calcitriol. The 21 patients were classified by histomorphometry as follows: osteitis fibrosa, 5; mild hyperparathyroidism, 3; normal histology, 3; aplastic, 6; and mixed lesions, 4. Four of 21 patients were surface positive for aluminum, and seven other patients stained positive for iron in bone. Serum parathyroid hormone (PTH) levels correlated directly with the bone formation rate (r = 0.84) and with eroded bone perimeter (r = 0.67). Eight of the nine patients with serum PTH levels above 125 pg/mL had marrow fibrosis. All patients with serum calcium levels < 10.0 mg/dL and serum PTH levels > 125 pg/mL had either osteitis fibrosa or mixed bone lesions--a group of patients that might benefit from aggressive vitamin D therapy. In contrast, an examination of patients with serum calcium levels > 10.0 mg/dL and serum PTH levels < 65 pg/mL correctly identified three out of three patients with aluminum-related bone disease. These findings suggest that measurements of serum intact PTH levels by the immunoradiometric assay method may be valuable in distinguishing high-turnover lesions from normal or low-turnover skeletal lesions in this population.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8338926     DOI: 10.1681/ASN.V3121938

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  19 in total

Review 1.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

2.  Cardiac, Inflammatory and Metabolic Parameters: Hemodialysis versus Peritoneal Dialysis.

Authors:  Silvia Lai; Alessio Molfino; Gaspare Elios Russo; Massimo Testorio; Alessandro Galani; Georgie Innico; Nicla Frassetti; Valentina Pistolesi; Santo Morabito; Filippo Rossi Fanelli
Journal:  Cardiorenal Med       Date:  2014-12-13       Impact factor: 2.041

3.  Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis.

Authors:  Rukshana Shroff; Mandy Wan; Evi V Nagler; Sevcan Bakkaloglu; Mario Cozzolino; Justine Bacchetta; Alberto Edefonti; Constantinos J Stefanidis; Johan Vande Walle; Gema Ariceta; Günter Klaus; Dieter Haffner; Claus Peter Schmitt
Journal:  Nephrol Dial Transplant       Date:  2017-07-01       Impact factor: 5.992

Review 4.  Searching the optimal PTH target range in children undergoing peritoneal dialysis: new insights from international cohort studies.

Authors:  Dieter Haffner; Franz Schaefer
Journal:  Pediatr Nephrol       Date:  2012-08-15       Impact factor: 3.714

5.  Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.

Authors:  Larry A Greenbaum; Ryszard Grenda; Ping Qiu; Irene Restaino; Amy Wojtak; Ana Paredes; Nadine Benador; Joel Z Melnick; Laura A Williams; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2005-03-23       Impact factor: 3.714

6.  Calcium and phosphate balance in adolescents on home nocturnal haemodialysis.

Authors:  Daljit K Hothi; Elizabeth Harvey; Elizabeth Piva; Laura Keating; Donna Secker; Denis F Geary
Journal:  Pediatr Nephrol       Date:  2006-04-01       Impact factor: 3.714

Review 7.  Bone disease in pediatric chronic kidney disease.

Authors:  Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2012-10-14       Impact factor: 3.714

Review 8.  New PTH assays and renal osteodystrophy.

Authors:  Isidro B Salusky; Harald Jüppner
Journal:  Pediatr Nephrol       Date:  2004-05-15       Impact factor: 3.714

9.  Bone histomorphometry in children prior to commencing renal replacement therapy.

Authors:  Simon Waller; Rukshana Shroff; Anthony J Freemont; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2008-05-15       Impact factor: 3.714

10.  What parathyroid hormone levels should we aim for in children with stage 5 chronic kidney disease; what is the evidence?

Authors:  Lesley Rees
Journal:  Pediatr Nephrol       Date:  2007-11-28       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.